医学临床研究
  2025年7月25日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (3): 412-414    DOI: 10.3969/j.issn.1671-7171.2022.03.025
  论著 本期目录 | 过刊浏览 | 高级检索 |
终末期肾病合并房颤患者血液透析治疗后低分子肝素抗凝出血的危险因素分析
赵辽辽, 常露元*
榆林市第二医院肾病学科,陕西 榆林 719000
Analysis of Risk Factors for Low Molecular Weight Heparin Anticoagulant Bleeding in End-stage Renal Disease Patients with Atrial Fibrillation after Hemodialysis
ZHAO Liao-liao, CHANG Lu-yuan
Department of Nephrology, Yulin Second Hospital, Yulin Shaanxi 719000
全文: PDF (1101 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨终末期肾病(ESRD)合并房颤患者血液透析治疗后低分子肝素抗凝出血的危险因素。【方法】回顾性分析本院收治的500例ESRD合并房颤患者的临床资料,统计分析患者血液透析治疗后低分子肝素抗凝出血的发生情况,采用Logistic回归分析ESRD合并房颤患者血液透析治疗后低分子肝素抗凝出血的影响因素。【结果】ESRD合并房颤患者血液透析治疗后低分子肝素抗凝出血事件发生率为7.40%(37/500)。出血组与未出血组患者在年龄、饮酒史、合并消化道疾病、周透析时间、血小板计数、低钙血症、进食辛辣食物方面比较差异均有统计学意义(P<0.05)。Logistic多因素分析显示,合并消化道疾病、周透析时间、低钙血症是ESRD合并房颤患者血液透析治疗后低分子肝素抗凝出血的独立影响因素(P<0.05)。【结论】合并消化道疾病、周透析时间、低钙血症是ESRD合并房颤患者血液透析治疗后低分子肝素抗凝出血的危险因素。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
赵辽辽
常露元
关键词 血液透析滤过肾疾病/并发症心房颤动/并发症肝素,低分子量/治疗应用    
Abstract:【Objective】To explore the risk factors of low molecular weight heparin anticoagulant bleeding in patients with end-stage renal disease (ESRD) with atrial fibrillation after hemodialysis treatment. 【Methods】A retrospective analysis of the clinical data of 400 ESRD patients with atrial fibrillation admitted to our hospital was performed. The incidence of low molecular weight heparin anticoagulant bleeding after hemodialysis in ESRD patients with atrial fibrillation was counted. Logistic regression analysis was used to analyze the multiple factors affecting low molecular weight heparin anticoagulant bleeding in patients with ESRD with atrial fibrillation after hemodialysis treatment. 【Results】The incidence of low-molecular-weight heparin anticoagulant bleeding events after hemodialysis in ESRD patients with atrial fibrillation was 7.40% (37/400). There were statistically significant differences between the bleeding group and the non-bleeding group in terms of age, drinking history, comorbid digestive tract disease, weekly dialysis time, platelet count, hypocalcemia, and spicy food eating habit(P<0.05). Logistic multivariate analysis showed that gastrointestinal diseases, weekly dialysis time, and hypocalcemia were independent influencing factors of low molecular weight heparin anticoagulant bleeding after hemodialysis in ESRD patients with atrial fibrillation (P<0.05). 【Conclusion】Gastrointestinal diseases, weekly dialysis time and hypocalcemia are risk factors for low-molecular-weight heparin anticoagulant bleeding in ESRD patients with atrial fibrillation after hemodialysis treatment.
Key wordsHemodiafiltration    Kidney Diseases/CO    Atrial Fibrillation/CO    Heparin, Low-Molecular-Weight/TU
收稿日期: 2021-10-22     
中图分类号:  R692  
通讯作者: * E-mail:changluyuan123@163.com   
引用本文:   
赵辽辽, 常露元. 终末期肾病合并房颤患者血液透析治疗后低分子肝素抗凝出血的危险因素分析[J]. 医学临床研究, 2022, 39(3): 412-414.
ZHAO Liao-liao, CHANG Lu-yuan. Analysis of Risk Factors for Low Molecular Weight Heparin Anticoagulant Bleeding in End-stage Renal Disease Patients with Atrial Fibrillation after Hemodialysis. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 412-414.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.03.025     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I3/412
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn